Section Arrow
Quote
VTVT.NASDAQ
- vTv Therapeutics
Quotes are at least 15-min delayed:2026/04/10 18:59 EDT
After Hours
Last
 36.56
0 (0.00%)
Bid
36.1
Ask
45
High 36.79 
Low 36.56 
Volume 132 
Regular Hours (Closed)
Last
 36.56
-0.74 (-1.98%)
Day High 
38.11 
Prev. Close
37.3 
1-M High
43.09 
Volume 
38.64K 
Bid
36.1
Ask
45
Day Low
35.04 
Open
37.31 
1-M Low
31.21 
Market Cap 
146.91M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 38.79 
20-SMA 37.49 
50-SMA 36.42 
52-W High 44 
52-W Low 14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.20/-4.70
Enterprise Value
146.91M
Balance Sheet
Book Value Per Share
16.36
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
After Hours 0.4292 -0.0727 -14.48%
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
After Hours 0.1223 -0.014 -10.27%
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
After Hours 0.1688 +0.0647 +62.15%
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
After Hours 6.6 -0.01 -0.15%
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
After Hours 3.77 +0.07 +1.89%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.